Day One

• Discussing the dynamic landscape of complement drug development, exploring novel targets and diverse therapeutic modalities and their potential across various diseases, including kidney, CNS, and ophthalmology
• Addressing critical operational and clinical challenges in complement therapy, delivery, and oral formulations
• Focussing on the scientific and translational hurdles that remain, covering the importance of developing robust biomarkers, predictive models the promising role of complement inhibitors in combination therapies

• Exploring the role of C3 fragments in the kidney in pathogenesis of C3G and other kidney disease
• Efficacy of C3/C3b inhibition in C3G patients
• Understanding the impact of C3/C3b inhibition on complement deposits in the kidney of C3G patients

• Highlighting the potential of RNA interference-based therapeutics in modulating complement-driven kidney diseases and offer insights into their mechanism of action
• Exploring the unique advantages of siRNA technology for complement inhibition in kidney disease, such as potentially targeted delivery and sustained effect
• Touching upon challenges and best practices in conducting large Phase 3 trials

Put a face to a name – this session is the perfect opportunity to get face-to-face time with key

opinion leaders, leading companies, and innovative researchers in the complement field.

Establish meaningful connections and gain individual insight beyond the papers and press

releases into the pioneering research and technique applications.